Twist Bioscience Corporation (TWST) Income Statement Analysis

See more : Getty Images Holdings, Inc. (GETY) Income Statement Analysis – Financial Results

Complete financial analysis of Twist Bioscience Corporation (TWST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Twist Bioscience Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Twist Bioscience Corporation (TWST)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.twistbioscience.com

About Twist Bioscience Corporation

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	312.97M	245.11M	203.57M	132.33M	90.10M	54.39M	25.43M	10.77M	2.27M
Cost of Revenue	179.63M	155.38M	119.33M	80.62M	61.41M	47.43M	32.19M	24.02M	9.42M
Gross Profit	133.35M	89.73M	84.24M	51.71M	28.69M	6.96M	-6.76M	-13.25M	-7.15M
Gross Profit Ratio	42.61%	36.61%	41.38%	39.08%	31.85%	12.80%	-26.59%	-123.09%	-315.20%
Research & Development	90.85M	106.89M	120.31M	69.07M	43.01M	35.68M	20.35M	19.17M	18.23M
General & Administrative	0.00	186.84M	210.55M	133.40M	102.07M	78.83M	42.55M	25.96M	18.07M
Selling & Marketing	0.00	2.90M	2.40M	2.50M	1.20M	1.30M	900.00K	100.00K	200.00K
SG&A	218.40M	189.74M	212.95M	135.90M	103.27M	80.13M	43.45M	26.06M	18.27M
Other Expenses	44.93M	10.26M	-1.09M	-1.37M	-182.00K	-265.00K	-121.00K	-55.00K	73.00K
Operating Expenses	354.18M	306.89M	333.26M	204.97M	146.27M	115.81M	63.80M	45.23M	36.50M
Cost & Expenses	533.81M	462.27M	452.59M	285.59M	207.68M	163.24M	95.99M	69.25M	45.93M
Interest Income	15.34M	14.37M	3.06M	435.00K	1.50M	3.03M	999.00K	412.00K	241.00K
Interest Expense	29.00K	5.00K	80.00K	367.00K	787.00K	1.29M	1.31M	905.00K	746.00K
Depreciation & Amortization	31.43M	29.31M	36.64M	11.99M	6.68M	6.31M	5.73M	5.02M	4.23M
EBITDA	-176.71M	-174.15M	-191.55M	-143.91M	-132.09M	-99.77M	-63.95M	-53.10M	-39.11M
EBITDA Ratio	-56.46%	-71.05%	-121.36%	-116.52%	-129.04%	-195.06%	-251.52%	-493.21%	-1,723.80%
Operating Income	-220.83M	-217.16M	-249.02M	-153.26M	-117.58M	-108.85M	-70.56M	-58.48M	-43.66M
Operating Income Ratio	-70.56%	-88.60%	-122.33%	-115.81%	-130.50%	-200.15%	-277.50%	-543.16%	-1,924.02%
Total Other Income/Expenses	12.67M	13.69M	6.50M	-1.30M	530.00K	1.47M	-435.00K	-548.00K	-432.00K
Income Before Tax	-208.17M	-203.47M	-228.27M	-154.03M	-139.55M	-107.38M	-70.99M	-59.03M	-44.09M
Income Before Tax Ratio	-66.51%	-83.01%	-112.14%	-116.39%	-154.88%	-197.44%	-279.21%	-548.25%	-1,943.06%
Income Tax Expense	560.00K	1.15M	-10.41M	-1.93M	382.00K	292.00K	242.00K	280.00K	819.00K
Net Income	-208.73M	-204.62M	-217.86M	-152.10M	-139.93M	-107.67M	-71.24M	-59.31M	-44.09M
Net Income Ratio	-66.69%	-83.48%	-107.02%	-114.94%	-155.31%	-197.98%	-280.16%	-550.85%	-1,943.06%
EPS	-3.60	-3.60	-4.04	-3.15	-3.57	-3.92	-2.68	-3.16	-2.35
EPS Diluted	-3.60	-3.60	-4.04	-3.15	-3.57	-3.92	-2.68	-3.16	-2.35
Weighted Avg Shares Out	58.02M	56.89M	53.89M	48.25M	39.19M	27.46M	26.61M	18.78M	18.78M
Weighted Avg Shares Out (Dil)	58.02M	56.89M	53.89M	48.25M	39.19M	27.46M	26.61M	18.78M	18.78M

Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024

April 18, 2024businesswire.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second...

Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

March 28, 2024businesswire.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome...

Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing

March 5, 2024businesswire.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced European Union (EU) in vitro diagnostic regulations (IVDR) compliant Twist Precision Dx...

7 Stocks Cathie Wood Is Still Loading Up On in Q1

February 13, 2024investorplace.com

You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.

7 Sexy Stocks That Will Continue to Outperform in 2024

February 11, 2024investorplace.com

While 2023 was the year of the Magnificent Seven, the seven outperforming stocks in this article are likely to be winners that will surge past the broader indices, such as the S&P 500 and the Nasdaq. The reason is that...

Twist Bioscience: Strong Performance In A Soft Market

February 7, 2024seekingalpha.com

Twist Bioscience reported strong results in the first quarter of FY2024, despite a tepid demand environment. Growth was somewhat exaggerated by lumpy NGS revenue, but overall the business is progressing well, particularly from a profitability perspective. Twist's share price has...

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

February 7, 2024businesswire.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform,...

Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

February 6, 2024businesswire.com

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science,...

Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT

February 5, 2024businesswire.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced technology early access of the Twist Flex Prep Ultra High-Throughput (UHT) Kit,...